Podium and Poster Presentations Demonstrate Ability of MaxCyte STX® and MaxCyte VLX® to Produce Antibody Titers Up to 2.7 g/L


Gaithersburg, MD, August 3, 2015  – MaxCyte®, Inc., the pioneer in scalable, high-performance cell transfection systems, will present data demonstrating the ability of MaxCyte flow electroporation to streamline antibody development and production by generating enough protein for multiple studies (mechanistic, formulation development and stability, large animal PK & PD, downstream process & purification development, structural analysis & crystallography, etc.) to be run in parallel. With the ability to produce up to 2.7 g/L in a single transfection, drug candidates can be moved more quickly from the benchtop to biomanufacturing.


Details of the MaxCyte presentation are as follows:

Event: BioProcessing Summit

Presentation: Generating High Titers with Flow Electroporation to Move From Bench to Development to Biomanufacturing

Presenter: Dr. James Brady Date: Tuesday, August 4, 2015

Time: 12:00 PM EDT

Location: Westin Copley Place, 10 Huntington Ave., Boston, MA 02116


Data also can be examined in a poster presentation on Wednesday, August 5 and Thursday, August 6. MaxCyte scientists will be available at Booth #304 to provide technical details on the use of flow electroporation for scalable transient gene expression.


About MaxCyte

MaxCyte is the leader in driving the next generation of cell-based medicines. MaxCyte’s cell modification technology, flow electroporation, is used for discovery, development, and manufacture of small molecule, biologic, and cell-based therapeutics. The MaxCyte GT® Flow Transfection System, the MaxCyte STX® Scalable Transfection System, and the MaxCyte VLX® Large Scale Transfection System enable the rapid development and consistent production of transfected cells for a broad array of applications.

For more information visit /